Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug: formulation and pharmacokinetic evaluation
Yuchen Zhang,1,* Xingwang Zhang,2,* Hongming Liu,2 Shaohui Cai,1 Baojian Wu21Department of Pharmacology, 2Division of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou, People’s Republic of China*These authors contributed equally to this workAbstract: Z-GP-Dox, the FAP&a...
Guardado en:
Autores principales: | Zhang Y, Zhang X, Liu H, Cai S, Wu B |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b4275c75bc9c4909b47d74672cce3b5c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
TPGS2000-DOX Prodrug Micelles for Improving Breast Cancer Therapy
por: Tang L, et al.
Publicado: (2021) -
Lymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nanostructured lipid carriers
por: Ni S, et al.
Publicado: (2017) -
pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects
por: Eduardo Burgarelli Lages, et al.
Publicado: (2021) -
Nanomicelles loaded with doxorubicin and curcumin for alleviating multidrug resistance in lung cancer
por: Gu Y, et al.
Publicado: (2016) -
Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy
por: Jiang Y, et al.
Publicado: (2020)